Skip to content

CytoMed Therapeutics (GDTC) IPO deck

Cytomed is focuses on translating its patented technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers.

This post is for subscribers only

Subscribe

Already have an account? Sign In

Latest